Zai Lab And Argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
Zai Lab And Argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
再鼎医药与Argenx获批在中国推出用于全身性重症肌无力的Efgartigimod alfa皮下注射剂
- First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China
- Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study
- 作为中国唯一获得国家药监局批准的皮下注射剂，为重症肌无力患者提供额外的灵活性和选择性。
- 第三阶段ADAPt-SC研究表明，与静脉注射相比，efgartigimod SC具有一致的临床效益和安全性。